Phaseline

Targets › VZGP5

VZGP5: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 3; Infectious disease; next expected readout Nov 2027.

Open in Phaseline: the race on VZGP5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MAXVAX Biotechnology Limited Liability CompanyVaricella Zoster Virus Envelope Glycoprotein E
Envelope glycoprotein E vaccine antigen
VZGP5, VZVPhase 3Herpes ZosterNov 2027

Conditions

Herpes Zoster (2)

Modalities

other (1)

Companies

MAXVAX Biotechnology Limited Liability Company (1)

Related targets

VZV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.